Phase II randomised study comparing Docetaxel, Cisplatin, 5-FU (DCF) with Cisplatin, 5-FU(CF) as induction chemotherapy in head and neck cancer

Shahid Beheshti University of Medical Sciences (Iran)0 个研究点目标入组 50 人开始时间: 2010年2月18日最近更新: 2015年1月13日

适应症

试验速览

暂无简介。

•1. Histological proven head and neck squamous cell carcinoma other than salivary gland tumour and sinonasal carcinoma
•2. Measurable primary tumour or lymph node or both
•3. T3 or T4 N0, T1-T4 N2-3
•4. Age from 16 till 70 years
•5. Performance status =2 according to ECOG classification
•6. No previous chemotherapy is allowed
•7. Adequate bone marrow, hepatic & renal functions
•7.1. Haemoglobin = 11 g/dl,
•7.2. Platelets = 100000 / mm3
•7.3. Absolute Neutrophil Count = 1500/mm3
•7.4. Bilirubin = Normal Value
•7.5. Transaminases = Normal Value
•7.6. Creatinine = 1 mg/dl
•8. Absence of neuropathy
•9. Absence of active co-morbid illness (uncontrolled infection, cardiopulmonary disease?)
•10. Complete initial work up within 2 weeks prior to first chemotherapy infusion

•1. Any metastasis
•2. Pregnant or lactating women.
•3. Other serious illness or medical conditions.
•4. Any chemotherapy administered before entering study
•5. Any patient with early stage cancer who can be treated without mutilating surgery
•6. Any contraindication for one of the drugs in chemotherapeutic regimens or radiotherapy

发起方

Shahid Beheshti University of Medical Sciences (Iran)